CAMBRIDGE, Mass., September 09, 2026--(BUSINESS WIRE)--Today, PhenoNet, Inc., an advanced clinical-stage biotechnology company developing therapies for neurodegenerative diseases, announced the ...
Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
The year is 2036. Researchers conducting a randomized clinical trial issue 200 volunteers with wearable devices to capture metrics on their heart rate, blood pressure, hormone levels and activity.
Today, PhenoNet, Inc., an advanced clinical-stage biotechnology company developing therapies for neurodegenerative diseases, announced the completion of recruitment and randomization on August 27, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results